tbuckley/cabot-search huggingface dataset:
Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment
Authors: Jennifer S. Hanberg, Evelyn Hsieh, Kathleen M. Akgün, Erica Weinstein, Liana Fraenkel, Amy C. Justice
Journal: Arthritis & Rheumatology (2021)

Objective To assess the incidence, presentation, and management of rheumatoid arthritis (RA) in patients with HIV, including the use of disease‐modifying antirheumatic drugs (DMARDs) in this immunosuppressed population. Methods Patients included in this study were from the Veterans Aging Cohort Study, a longitudinal cohort of veterans with HIV and age‐, race‐, and site‐matched uninfected veterans. We identified all patients who had ≥1 rheumatologist‐generated International Classification of Diseases, Ninth Revision (ICD‐9) or Tenth Revision (ICD‐10) code for RA and whose serum samples were tested for rheumatoid factor (RF) and anti–cyclic citrullinated peptide (anti‐CCP) antibodies. To further confirm the diagnosis of RA, medical charts were reviewed to verify whether patients met the American College of Rheumatology/European Alliance of Associations for Rheumatology 2010 criteria for RA. We recorded DMARD use and adverse effects during the first contiguous course of treatment (i.e., &gt;6 months of no interruption in DMARD treatment). Results This study included 56,250 patients with HIV and 116,944 uninfected individuals over 2,384,541 person‐years. Of the 2,748 individuals in this cohort who were reviewed for a diagnosis of RA based on ICD‐9 or ICD‐10 codes, incident RA was identified in 215 individuals, including 21 patients with HIV. The incidence rate ratio of RA for patients with HIV compared to uninfected individuals was 0.29 (95% confidence interval 0.19–0.48). Most of the patients diagnosed as having RA (88%) were seropositive for RA‐associated autoantibodies (RF and/or anti‐CCP). However, high autoantibody titers were less frequent in RA patients with HIV compared to RA patients without HIV. In total, 5% of RA patients with HIV (1 of 21) had both high titers of anti‐CCP and high titers of RF, compared to 41% of uninfected individuals (81 of 194). DMARDs were prescribed in 71% of RA patients with HIV (15 of 21) compared to 94% of RA patients without HIV (183 of 194). There was no indication that the DMARD safety profile was worse among RA patients with HIV who were prescribed DMARDs (n = 10 assessed) compared to RA patients without HIV who were prescribed DMARDs (n = 158 assessed). Conclusion In this cohort, incident RA was less common in patients with HIV compared to uninfected individuals. Moreover, compared to RA patients without HIV, the seropositivity rate and titers of RA‐specific autoantibodies were lower among RA patients with HIV, and those with HIV were prescribed DMARDs less frequently than those without HIV.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Authors: Emma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, Kim A Papp, Aileen L Pangan, Andrew Blauvelt, Diamant Thaçi, Chia-Yu Chu, H Chih-ho Hong, Norito Katoh, Amy S Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R Tenorio, Alvina D Chu, Alan D Irvine
Journal: The Lancet (2021)
miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis
Authors: Jing Wang, Hong-Lin Qian, Sheng-Yu Chen, Wei-Pin Huang, Dan-Ni Huang, Hong-Ye Hao, Ke-Feng Ren, Yun-Bing Wang, Guo-Sheng Fu, Jian Ji
Journal: Bioactive Materials (2021)

The in-stent restenosis (IRS) after the percutaneous coronary intervention contributes to the major treatment failure of stent implantation. MicroRNAs have been revealed as powerful gene medicine to regulate endothelial cells (EC) and smooth muscle cells (SMC) in response to vascular injury, providing a promising therapeutic candidate to inhibit IRS. However, the controllable loading and eluting of hydrophilic bioactive microRNAs pose a challenge to current lipophilic stent coatings. Here, we developed a microRNA eluting cardiovascular stent via the self-healing encapsulation process based on an amphipathic poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) (PCL-PEG-PCL, PCEC) triblock copolymer spongy network. The miR-22 was used as a model microRNA to regulate SMC. The dynamic porous coating realized the uniform and controllable loading of miR-22, reaching the highest dosage of 133 pmol cm
Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials
Authors: Tom GH Wiggers, Marinus Winters, Noortje AC Van den Boom, Hidde J Haisma, Maarten H Moen
Journal: British Journal of Sports Medicine (2021)

Objective Stem cell therapy is increasingly used for knee osteoarthritis (KOA). We aimed to review the evidence of autologous mesenchymal stem cell therapy on pain, function and severity on imaging in KOA. Design Systematic review of randomised controlled trials (RCTs). Eligibility criteria RCTs evaluating autologous mesenchymal stem cell (MSC) therapy on patient-reported outcome measures and disease severity. Data sources Seven databases were searched until 31 December 2020. Risk of bias and data synthesis Risk of bias was assessed using the ROB V.2. We used Grading of Recommendations Assessment, Development and Evaluation to appraise the certainty of the evidence. Data were synthesised descriptively. Results Fourteen RCTs were included. A total of 408 patients with KOA received MSC therapy derived from bone marrow, adipose tissue or activated peripheral blood. After 1 year, 19 of 26 (73%) clinical outcome measures improved with MSCs compared with control. In the MSC group, patients improved by 1.8–4.4 points on the Visual Analogue Scale (0–10) and 18–32 points of the Knee Osteoarthritis Outcome Score (0–100). Four studies showed better disease severity on imaging after MSC compared with control at 1 year. Ten of 14 (71%) RCTs were at high risk of bias on all outcomes. No serious adverse events were reported after MSC therapy during a maximum of 4 years follow-up. Conclusion We found a positive effect of autologous MSC therapy compared with control treatments on patient-reported outcome measures, and disease severity. The certainty of this evidence was low to very low. PROSPERO registration number CRD42019120506
Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model
Authors: Xiuzhang Xu, Dawei Chen, Xin Ye, Wenjie Xia, Yaori Xu, Yangkai Chen, Yuan Shao, Jing Deng, Haoqiang Ding, Jing Liu, Jiali Wang, Heyu Ni, Yongshui Fu, Sentot Santoso
Journal: Blood (2021)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Authors: Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Luca Baldini, Meral Beksac, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Jelena Bila, Mario Boccadoro, Michele Cavo, Javier De La Rubia Comos, Sosana Delimpasi, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman
Journal: The Lancet Oncology (2021)
Water-soluble PANI:PSS designed for spontaneous non-disruptive membrane penetration and direct intracellular photothermal damage on bacteria
Authors: Huanfeng Tang, Yifan Liu, Bing Li, Bo Shang, Jiacheng Yang, Congrou Zhang, Lijun Yang, Kezheng Chen, Wei Wang, Jianfeng Liu
Journal: Bioactive Materials (2021)

The major challenge in the field of antibacterial agents is to overcome the low-permeability of bacteria cell membranes that protects the cells against diverse drugs. In this work, water-soluble polyaniline (PANI)-poly (p-styrenesulfonic acid) (PSS) (PANI:PSS) is found to spontaneously penetrate bacteria cellular membranes in a non-disruptive way, leaving no evidence of membrane poration/disturbance or cell death, thus avoiding side effects caused by cationic ammonia groups in traditional ammonia-containing antibacterial agents. For aqueous synthesis, which is important for biocompatibility, the polymer is synthesized via an enzyme-mimetic route relying on the catalysis of a nanozyme. Owing to its fluorescent properties, the localization of as-prepared PANI:PSS is determined by the confocal microscope, and the results confirm its rapid entry into bacteria. Under 808 nm near-infrared (NIR) irradiation, the internalized PANI:PSS generates local hyperthermia and destroys bacteria highly efficiently from inside the cells due to its excellent photothermal effects. Staphylococcus aureus (S. aureus), Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli) could be effectively eliminated as well as the corresponding bacterial biofilms. Results of in vivo antibacterial experiments demonstrate excellent antibacterial activities of the water-soluble PANI:PSS without side effects. Therefore, the prepared water-soluble polymer in this study has great potential in the treatment of various bacterial infections.
Matt Morgan: “Less grit, more quit” has its benefits
Authors: Matt Morgan
Journal: BMJ (2021)

Sundays are much better nowadays. They used to start with gentle encouragement for my daughter to practise the piano. Then mild threats. Then bribes. Five minutes of her pressing the wrong keys would be followed by, “Do I have to do it today?” The sunk costs of the grades she’d already done and the books we’d already bought would lead me to exclaim, “Yes!” More grit needed, I’d think.

Monday morning at work, I’d try to put this grit to good use. We all have projects we keep deferring, roles we’ve grown tired of, or entire jobs that just pass the time. Yet we don’t quit. We grit. Because quitting is a dirty …
Abstract 14035: Feasibility of Using Mobile Health Technology to Deliver Life’s Simple 7 Messages for Atrial Fibrillation Management
Authors: Meghan Reading Turchioe, Suzanne Bakken, Ruth M Masterson Creber
Journal: Circulation (2019)

Introduction: AHA’s Life’s Simple 7 (LS7) defines key behaviors for ideal cardiovascular health. LS7 delivered via mobile health (mHealth) has not be explored to reduce behavioral risk factors for ...
High-Intensity Healthcare Utilization and Costs Among Older 10+y Survivors of Allogeneic Blood or Marrow Transplantation (BMT): A Report from the BMT Survivor Study-2 (BMTSS-2)
Authors: Eric Kim, Smita Bhatia, Lindsey Hageman, Jessica Wu, Liton F. Francisco, Emily Ness, Mariel Parman, Michelle Kung, Alysia Bosworth, Stephen J. Forman, Daniel J. Weisdorf, Mukta Arora, Saro H. Armenian, Kelly Kenzik
Journal: Blood (2017)
POS0138 ALTERED RISK OF GOUT ACCORDING TO CHANGE OF METABOLIC PARAMETERS IN YOUNG ADULTS
Authors: Y. Eun, I. Y. Kim, K. D. Han, S. Y. Kang, S. Lee, H. S. Cha, E. M. Koh, H. Kim, J. Lee
Journal: Annals of the Rheumatic Diseases (2021)

Background: Many studies have shown a link between gout and metabolic syndrome (MetS). It is well known that lifestyle modifications such as weight reduction and abstinence from alcohol are effective in the treatment of gout, but data are lacking on how exactly the change of metabolic parameters affects gout. Objectives: The purpose of this study was to investigate the relationship between gout risk and metabolic parameters in a nationwide population based young adult cohort, and to determine whether changes in metabolic parameters affect gout risk changes. Methods: Among adults aged 20-39 years who participated in national health check-up programs from 2009 to 2012, a total of 6,290,914 subjects were included in the study, excluding subjects who were previously diagnosed with gout. To determine the effect of changes in metabolic parameters on gout incidence, 2,701,138 subjects who participated in the health examination once more 2 years later were used for the analysis. Outcome was defined as the occurrence of gout, when the ICD-10 code (M10) was registered twice in the claim database. The Cox proportional hazard model and Kaplan Meier curve were used for the analysis. Results: The incidence rate of gout was higher in those with MetS compared to those without (10.1 vs. 3.6 per 1,000 person-years). The risk of gout in people with MetS was 85% higher (adjusted HR 1.85, 95% CI 1.83-1.87) and was more significant in men than in women (adjusted HR 1.88 in male and 1.56 in female). Each component of MetS was also associated with increased gout risk, and hypertriglyceridemia showed the highest adjusted HR. The greater the number of MetS components, the higher the gout risk. The risk of gout was 70% higher in those who had MetS consistently (adjusted HR 1.71, 95% CI 1.67-1.75) and 44% higher in those with newly developed MetS (adjusted HR 1.47, 95% CI 1.40-1.48) than those who did not have MetS at the two health examinations. Similar risk patterns were observed according to the change of each metabolic parameter. Among the metabolic parameters, the change in hypertriglyceridemia was associated with the greatest difference in the change in gout risk. Conclusion: In young adults, MetS was associated with a higher risk of gout, especially with more components, the higher the risk. Since the occurrence of MetS is associated with an increased risk of gout, prevention of MetS would be important to reduce gout incidence. Disclosure of Interests: None declared
AB0127 COMBINATION THERAPY WITH METHOTREXATE AND QUALITY OF LIFE IN RHEUMATOID ARTHRITIS
Authors: S. Abdellaoui, S. Lefkir
Journal: Annals of the Rheumatic Diseases (2021)

Background: The level of quality of life in patients with rheumatoid arthritis (RA) is often overlooked. These patients suffer from an often-precarious quality of life resulting in pain, joint destruction and fatigue. Objectives: The main objective of this study was to compare the level of quality of life in patients with RA receiving treatment with disease-modifying anti-rheumatic drugs (DMARDs): monotherapy (biological only) versus combination therapy with methotrexate. Methods: We performed a descriptive study of 56 patients with RA meeting the criteria of the ACR 2010. The SPSS.20 software was used for statistical analyses. Results: These were 56 patients: 93% women and 7% men, mean age 46.74 years with an average duration of the disease of 14.74 years. 28 patients were on rituximab, 19 patients on tocilizumab and 9 patients on TNFi. The mean HAQ was 1.11. 52.38% of patients were on biological alone as monotherapy. The Compliance Questionnaire Rheumatology score (CQR19) was 55.15 / 100, the RAID (Rheumatoid Arthritis Impact of Disease) score was 3.08 / 10, the SF36 of 56.01 / 100, the AIMS score of 2.10 / 10 for social activity, 2.44 / 10 for pain, 3.32 / 10 for depression and 4.06 for physical activity. The comparison between the 2 groups (Combination therapy vs monotherapy) did not find any significant difference in terms of quality of life parameters: An SF-36 score&gt; 55 was found in 56% in patients on combination therapy vs. 44% on monotherapy, the RAID score was 3.02 vs. 3.12, AIMS social activity 2.08 vs 2.13, AIMS pain 2.33 vs 2.59, AIMS activity physics of 4 vs 4.11. Conclusion: Our study did not demonstrate any superiority of the combination with methotrexate in improving quality of life. The use of biotherapy in patients with RA has been shown to be an important pharmacological strategy for the overall management of the disease. References: [1]Lavielle.M and Dougados.M. Targeted therapies in rheumatoid arthritis: Combination with conventional synthetic disease modifying antirheumatic drugs or monotherapy? Jone Bone Spine 2018; 85:3-9. Disclosure of Interests: None declared
Emerging Brain‐Pathophysiology‐Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains‐on‐a‐Chip
Authors: Seokyoung Bang, Songhyun Lee, Nakwon Choi, Hong Nam Kim
Journal: Advanced Healthcare Materials (2021)

Abstract Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of the structural and functional integrity of the central and peripheral nervous systems. Millions of people suffer from degenerative brain diseases worldwide, and the mortality continues to increase every year, causing a growing demand for knowledge of the underlying mechanisms and development of therapeutic targets. Conventional 2D‐based cell culture platforms and animal models cannot fully recapitulate the pathophysiology, and this has limited the capability for estimating drug efficacy. Recently, engineered platforms, including brain organoids and brain‐on‐a‐chip, have emerged. They mimic the physiology of brain tissue and reflect the fundamental pathophysiological signatures of neurodegenerative diseases, such as the accumulation of neurotoxic proteins, structural abnormalities, and functional loss. In this paper, recent advances in brain‐mimetic platforms and their potential for modeling features of neurodegenerative diseases in vitro are reviewed. The development of a physiologically relevant model should help overcome unresolved neurodegenerative diseases.
POS0497 A RELIABILITY EXERCISE USING CONSENSUAL DEFINITIONS FOR THE ULTRASONOGRAPHY OF THE SHOULDER IN RHEUMATOID ARTHRITIS
Authors: K. Ben Abdelghani, S. Miladi, I. Mahmoud, H. Ajlani, E. Haddouche, A. Maghraoui, S. Slimani, A. Fazaa, A. Ben Tekaya, L. Abdelmoula, A. Laatar, R. Bahiri
Journal: Annals of the Rheumatic Diseases (2021)

Background: Although numerous clinical tests for the diagnosis of painful shoulder are available, differentiating articular from periarticular lesions may be difficult in daily practice. Fortunately, the precise diagnosis of shoulder pain in RA benefited from a reliable imaging modality to detect its exact origin as ultrasonography (US). Objectives: This study aimed to assess the intraobserver and interobserver reliabilities of the ultrasonographic findings for patients with established RA having shoulder pain in a patient-based exercise among maghrebian rheumatologists experts on US. Methods: A total of 7 operators examined 10 patients in 2 rounds independently and blindly of each other. Each patient underwent a US scanning of the painful shoulder in four sites based on US technical guidelines of the European society of musculoskeletal radiology: long head of Biceps (LHB), subscapularis recess, posterior recess and axillary recess. The presence of a subdeltoid or subcoracoid bursitis or the presence of transfixiant tear of the suprasupinatus were notified if present. Intra and inter-observer reliabilities were calculated. Results: Intraobserver reliability was excellent for GS synovitis in subscapularis and posterior recesses (k=0.91 for both) and for subcoracoid bursitis (k=0.81). It was good in case of presence of a subdeltoid bursitis (k=0.79), transfixiant tear of the suprasupinatus (k=0.65), GS synovitis and effusion in LHB (k=0.67 and 0.6 respectively) and subdeltoid bursitis (k= 0.79). Interobserver reliability was good for PD for LHB signals searched longitudinally (k=0.78) and transversally (k=0.78). It was moderate for GS for LHB synovitis (k=0.55). Interobserver agreement was poor for effusion and GS synovitis for subscapularis, posterior and axillary recesses. It was very poor and/or absent for PD signals in these recesses. Conclusion: US is a reliable imaging tool for shoulder in RA especially with regard to LHB effusion, GS and PD synovitis. Interobserver reliability of subscapularis, posterior and axillary recesses could be optimized by standardization of sites to assess. References: [1]Bruyn G a. W, Naredo E, Möller I, Moragues C, Garrido J, de Bock GH, et al. Reliability of ultrasonography in detecting shoulder disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:357–61. Disclosure of Interests: None declared
Cancer incidence and mortality in Greenland 1983-2014, including comparison with the other Nordic countries.
Authors: Umbreen Yousaf, Elizabeth Zetlitz, Henrik Trykker, Gerda Engholm, Niels Christian Christensen, Hans H Storm, Frank Sejersen, Peter Bjerregaard, Lau Casper Thygesen
Journal: Journal of Clinical Oncology (2018)

e13590 Background: During the last decades social and life-style changes have altered the disease pattern in Greenland with an increase in the incidence of several life-style related diseases. Our aim is to present the incidence and mortality of cancer in Greenland and compare the results with the other Nordic countries. Methods: The data is obtained from The Danish Cancer Registry and The Danish Register of Causes of Death. Comparable data on cancer incidence and mortality in Denmark, Finland, Iceland, Norway, Sweden and Greenland are available for analysis through a collaboration of The Nordic Cancer Registries (NORDCAN). We included all patients living in Greenland and diagnosed with a cancer during 1983 to 2014. Results: The total number of cancers for the study period was 4,716 (2,362 among women and 2,354 among men). The cancer incidence was highest for gastrointestinal cancer and respiratory cancer for both sexes. Furthermore the incidence of cancer of the female genital organs and breast cancer was high among women, whereas the incidence of cancer of the lip, oral cavity and pharynx was high among men. Notably higher incidence rates of cancer of the lip, oral cavity and pharynx, respiratory cancer, and cancer of unknown sites were seen compared to the other Nordic countries. The incidence rates of breast cancer and cancer of male genital organs were lower than the other Nordic countries. Cancer-specific mortality rates were much higher in Greenland compared to the other Nordic countries. The time trend from 1983 to 2014 showed a significant increase in cancer incidence in Greenland, but with no change in the cancer-specific mortality. Conclusions: The trends in cancer incidence and mortality in Greenland compared to the other Nordic countries have not been reported earlier. These data underline a need to focus on cancer-specific mortality in Greenland and prevention of high-incidence cancers related to well-established risk factors. Disparities in cancer incidence and mortality are also seen among other Inuit communities and indigenous people in general. Enhanced attention to indigenous people to ensure high-quality and high-value cancer care is necessary for a better worldwide cancer control.